ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022
Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir.Microbiology spectrum · 2024Trial
- Pandemic research in a small island society-a narrative review of research contributions during the SARS-CoV-2 pandemic in the Faroe Islands.International journal of circumpolar health · 2026Review
- Article
- An investigation into the impact of temporality on COVID-19 infection and mortality predictions: new perspective based on Shapley Values.BMC medical research methodology · 2025Article
- What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?The Journal of infectious diseases · 2024Article
- Comparative Performance of COVID-19 Test Methods in Healthcare Workers during the Omicron Wave.Diagnostics (Basel, Switzerland) · 2024Article
- Variant- and vaccination-specific alternative splicing profiles in SARS-CoV-2 infections.iScience · 2024Article
- Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.Viruses · 2024Article
- Acute and persistent symptoms of COVID-19 infection in school-aged children: a retrospective study from China.BMC public health · 2024Article
- The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.Frontiers in immunology · 2024Article
- SARS-CoV-2 anti-RBD and anti-N protein responses are differentially regulated between mother-child pairs: insight from a national study cohort at the Faroe Islands.Frontiers in immunology · 2024Article
- Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.Human vaccines & immunotherapeutics · 2023Article
- Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China.Emerging microbes & infections · 2023Article
- Variant- and Vaccination-Specific Alternative Splicing Profiles in SARS-CoV-2 Infections.bioRxiv : the preprint server for biology · 2023Article
- Coronary microvascular health in symptomatic patients with prior COVID-19 infection: an updated analysis.European heart journal. Cardiovascular Imaging · 2023Article
- Article
- Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center in Herat, Afghanistan.PLOS global public health · 2023Article
- Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.Frontiers in immunology · 2023Article
- Epidemiological and laboratory characteristics of Omicron infection in a general hospital in Guangzhou: a retrospective study.Frontiers in public health · 2023Article
- Vaccine versus infection - COVID-19-related loss of training time in elite athletes.Journal of science and medicine in sport · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOmicron appears to lead to a milder illness for patients compared with previous COVID-19 variants. However, not all infected with Omicron would describe their illness as mild. In this study, we investigate the experienced severity and symptoms of the Omicron variant.
methodsWe conducted a nationwide cross-sectional study, including 5036 individuals of all ages, consisting of reverse transcription-polymerase chain reaction confirmed SARS-CoV-2 cases from 1 January to 31 January 2022 (n = 4506) and a control group without SARS-COV-2 infection in December 2021 or January 2022 (n = 530). Omicron was dominant during this period. Cases were asked about their acute symptoms and answered a web-based questionnaire 10-30 days after their positive test while controls were asked about symptoms during the past week.
resultsAmong cases, 97% reported at least one symptom during the acute phase compared with 79% of controls. Just over half the cases assessed their illness as asymptomatic or mild, whereas 46% assessed their illness as moderate or severe. Children reported fewer symptoms and less severe illnesses than adults (P <0.001). The largest risk differences (RDs) between adult cases and controls due to symptoms were observed for fever (RD = 60.6%, confidence interval [CI] 57.4-63.6), fatigue (RD = 49.6%, CI 44.1-54.7), and chills (RD = 48.8%, CI 43.8-53.2).
conclusionMost of those infected with Omicron experience symptoms, and the Omicron variant appears to lead to less severe disease. However, this does not mean that all the infected experience an Omicron infection as mild. The unprecedented rate of Omicron infections worldwide leads to urgent questions about the rate of long COVID after Omicron infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.